Contents lists available at ScienceDirect

# Journal of Fluorine Chemistry

journal homepage: www.elsevier.com/locate/fluor

Short Communication

# Synthesis of trifluoromethyl moieties by late-stage copper (I) mediated nucleophilic fluorination

Antonio Bermejo Góme<sup>a,c,\*</sup>, Miguel A. Cortés González<sup>b,c</sup>, Marvin Lübcke<sup>b,c</sup>, Magnus J. Johansson<sup>d</sup>, Magnus Schou<sup>a,c</sup>, Kálmán J. Szabó<sup>b,c,\*\*</sup>

<sup>a</sup> AstraZeneca Personalised Healthcare and Biomarkers, PET Centre at Karolinska Institutet, Karolinska Universitetssjukhuset Solna, R5:02, SE-171 76 Stockholm, Sweden

<sup>b</sup> Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, SE-106 91 Stockholm, Sweden

<sup>c</sup> Stockholm Brain Institute, Karolinska Intitutet, SE-171 77 Stockholm, Sweden

<sup>d</sup> Cardivascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, SE- 431 83, Sweden

### ARTICLE INFO

Article history: Received 21 November 2016 Received in revised form 23 December 2016 Accepted 30 December 2016 Available online 3 January 2017

Keywords: Nucleophilic fluorination Copper Trifluoroacetate Trifluoroacetamide

# 1. Introduction

The introduction of a fluorine atom into a moiety can considerably affect the physicochemical properties of bioactive molecules. In particular, the trifluoromethyl group (CF<sub>3</sub>) is an important substituent in medicinal chemistry that is widely represented in drugs and druglike molecules [1]. Late-stage introduction of fluorine into organic compounds has kept the attention of synthetic organic chemists in the last years due to the applicability of the artificial <sup>18</sup>F isotope in positron emission tomography (PET) [2–4]. While an enormous amount of new fluorination reactions have been developed [5], late-stage nucleophilic introduction of fluorine still remains as a challenge [2]. This could be attributed to the decreased nucleophilicity of the fluoride

http://dx.doi.org/10.1016/j.jfluchem.2016.12.017 0022-1139/© 2017 Elsevier B.V. All rights reserved. anion due to its high solvation energy [6]. For this reason the use of harsh reaction conditions including high temperatures [7] (>140 °C) and/or activators are usually required [8–11]. This difficulty is accentuated when the nucleophilic fluorination is desired at a fluorinated carbon center. The presence of one or two fluorine atoms in the carbon center will hinder such substitution owing to the electrostatic effect of the current fluorine substitution [18].

The  $(PPh_3)_3CuF$  complex was reported for the first time in 1970 [12] and it is considered to be the closest related compound to Cu(I) F [13,14]. Although  $(PPh_3)_3CuF$  has been used as intermediate in the synthesis of the well-known trifluoromethylating agent  $(PPh_3)_3CuCF_3$  [15], its reactivity as nucleophilic fluorinating agent has not been studied in detail. To the best of our knowledge, there are only two reports in this context. First, the group of Konovalov reported the synthesis of 1-fluoro-2-nitrobenzene from 1-bromo-2-nitrobenzene using  $(PPh_3)_3CuF$  [16]. Another paper was published by the Szabó group on regio- and stereoselective nucleophilic fluorination of allyl chlorides using the same  $(PPh_3)_3CuF$  complex, showing the promising properties of this complex as a nucleophilic fluorine source [17].

АВЅТ Я А С Т

The nucleophilic fluorination of bromodifluoromethyl derivatives mediated by the complex (PPh<sub>3</sub>)<sub>3</sub>CuF is described. Under the reaction conditions, different trifluoroacetates, trifluoroketones, trifluoroarenes and trifluoroacetamides were obtained in good yields.

© 2017 Elsevier B.V. All rights reserved.







<sup>\*</sup> Corresponding author at: AstraZeneca Personalised Healthcare and Biomarkers, PET Centre at Karolinska Institutet, Karolinska Universitetssjukhuset Solna, R5:02, SE-171 76, Stockholm, Sweden.

<sup>\*\*</sup> Corresponding author at: Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, SE-106 91, Stockholm, Sweden.

E-mail address: antonio.bermejo-gomez@astrazeneca.com (A. Bermejo Góme).

 Table 1

 Screening of reaction conditions.

$$Br \xrightarrow{O}_{F} f \xrightarrow{PPh_{3}_{3}CuF} (I, 1.4 \text{ equiv.}) \xrightarrow{O}_{F} f \xrightarrow$$

Entry	Solvent	Temperature (°C)	Conversion (%) <sup>b</sup>
1	CDCl <sub>3</sub>	40	<1
2	CDCl <sub>3</sub>	80	5
3	THF	80	11
4	1,4-Dioxane	80	11
5	Toluene	80	3
6	DMF	80	69
7	DMF	100	90

 $^{\rm a}$  Reaction conditions: 1a (0.1 mmol), solvent (0.3 mL), dissolved and heated in the corresponding solvent and temperature under an argon atmosphere for 2.5 h.

<sup>b</sup> Conversion determined by <sup>19</sup>F NMR spectroscopy from the reaction crude.

In this paper we present a new late-stage nucleophilic fluorination process for the synthesis of trifluoromethyl moieties ( $CF_3$ ). This method is based on the halogen exchange reaction between the corresponding difluorobromomethyl derivative ( $R-CF_2Br$ ) and the easily available copper (I) complex ( $PPh_3$ )<sub>3</sub>CuF.

# 2. Results and discussion

Our initial investigation started with the transformation of a model substrate, ethyl 2-bromo-2,2-difluoroacetate (**1a**) into the corresponding trifluoroacetate (**2a**) using the  $(PPh_3)_3CuF$  complex I (Table 1). First, we screened different solvent and temperatures. When CDCl<sub>3</sub> was used as solvent, low conversions were observed at 40 or 80 °C (Table 1, entries 1 and 2). The use of more polar solvents, such as THF or 1,4-dioxane, gave similar results and 11% of conversion was observed for both solvents (Table 1, entries 3 and 4). The use of the non-polar solvent toluene did not improve the conversion (Table 1, entry 5). Notably, the conversion of the reaction was increased up to 69% at 80 °C for 2.5 h when using DMF as solvent (Table 1, entry 6). When increasing the temperature from 80 to 100 °C the reaction proceed with a 90% conversion (Table 1, entry 7).

With these results in hand, we investigated the scope of the reaction (Scheme 1). All trifluoromethylated products obtained in the fluorination reactions with (PPh<sub>3</sub>)<sub>3</sub>CuF were relatively unpolar and by consequence difficult to separate from PPh<sub>3</sub> (arising from the decomposition of the Cu-F complex). Thus, even after careful purification the product samples usually contained varying amounts of PPh<sub>3</sub>. Hence, for practical reasons and because this is not a problem for a possible PET application due to the use of HPLC purifications, the vields provided in Scheme 1 were determined by <sup>19</sup>F NMR using an internal standard. All products were prepared by alternative methods and fully characterized (see Experimental Section 4.8) before being identified by <sup>1</sup>H and <sup>19</sup>F NMR spectroscopy in the crude reaction mixtures. Different bromodifluoroacetates with alkyl chains (1a-d) were well tolerated in the reaction, yielding the corresponding trifluoroacetates 2a-d in excellent yields (89–92%). Substrates containing bulky substituents as 1e, derived from (-)-menthol, also gave excellent results (88% yield). Substrates with phenoxy or Nphthalimide substituents (1f-g) gave the corresponding trifluoroacetates (2f-g) in good yields (83% and 68%, respectively). Only in the case of the benzyl derivative **1h** the yield was diminished to 55%, due to the formation of by products in the reaction mixture. We obtained an excellent yield in the fluorination of 2,2,2bromodifluoroketone 1i (96%). However, the enolyzable 2,2,2bromodifluoroketone 1j provided low yield of the product 2j in a complex mixture of decomposition products.

Next, we turned our attention to the nucleophilic fluorination of benzylic positions with the purpose of synthesizing trifluoromethyl arenes in a late-stage fashion (Table 2). For this particular reaction, we found that there was no single solvent suitable for all tested substrates. For the *p*-Ph substituted substrate **3a**, a 93% was obtained using CDCl<sub>3</sub> at 70 °C (Table 2, entry 1). With this promising result in hand, we focused our attention into more challenging substrates such as electron deficient arenes [8,9,18]. When a *p*-CN group was incorporated in the substrate (**3b**), only 25% was obtained using toluene at 120 °C (Table 2, entry 2). Substrates bearing a *p*-Br or *p*-OCF<sub>3</sub> substituent gave moderate yields, 49% and 40%, respectively using 1,2-dichloroethane at 100 °C (Table 2, entries 3 and 4). Substrates with the strong electron-withdrawing groups *p*-CF<sub>3</sub> and *p*-CF<sub>2</sub>Br (**3e** and **3f**, respectively) yielded the corresponding trifluoromethyl arenes





<sup>a</sup>Reaction conditions (unless otherwise noted): **1a-j** (0.1 mmol), DMF (0.3 mL), heated at the 100 °C under an argon atmosphere for 2.5 h. Yield determined by <sup>19</sup>F NMR spectroscopy using 2,2,2-trifluorotoluene as internal standard. <sup>b</sup>Using CDCl<sub>3</sub> at 70 °C.

**4e** and **4f** in low to moderate yields using DMF at 100 °C (Table 2, entries 5 and 6).

We also tested the complex I in the transformation of bromodifluoroacetamides (5a-j) into the corresponding trifluoroacetamides (6aj). Low yields (36-52%, Scheme 2) were obtained for the model substrates **5a-c** (Scheme 2). Recently, we have reported the use of nucleophilic organoactivators (i.e. DBU) for the debrominative <sup>18</sup>F-fluorination of bromodifluoroacetamides using Bu₄NF<sup>[18</sup>F] as nucleophilic fluorinating agent [10]. In this case a similar effect was observed when DBU was added as additive in the nucleophilic fluorination using (PPh<sub>3</sub>)<sub>3</sub>CuF. Thus, N,N-dialkyltrifluoroacetamides 6a-c were obtained in good yields (74-87%, Scheme 2). In this case, substrates with benzyl derivatives substituents (5d-e) were well tolerated, yielding the corresponding trifluoroacetamides (6d-e) in good yields (73-81%). Oxygen containing substrates, such as the morpholine derivative **5f** or the ketal protected carbonyl 5g were tolerated, yet they provided somewhat lower yields of the trifluoromethylated analogues (6fg). Other bromodifluoroacetamides such as fluorenone derivative 5 h and N-methyl-N-tosylacetamide 5i provided very low yields of the corresponding trifluoroacetamides (6h-j) when DBU was used. In these cases hydrolysis of the amides could occur in the basic media. However, good to moderate yields were obtained (88% and

Table 2Substrate scope of trifluoromethyl arenes.<sup>a</sup>



<sup>a</sup> Reaction conditions: **3a-f** (0.1 mmol), solvent (0.3 mL), heated at the indicated temperature under an argon atmosphere for 4 h. Yield determined by <sup>19</sup>F NMR spectroscopy using 2,2,2-trifluoroacetophenone as internal standard.

56% respectively) when DBU was not present. The Weinreb amide derivative **6j** was obtained in similar yields with and without DBU.

# 3. Conclusion

In summary, we have demonstrated that the complex  $(PPh_3)_3CuF$  is an excellent nucleophilic fluorination agent in the synthesis of trifluoromethyl moieties from the corresponding bromodifluoro derivatives. In general, the reaction proceeds in DMF as the solvent at 100 °C in short reaction times and without the addition of external ligands. In the case of less reactive substrates, the use of activators as DBU has a beneficial effect accelerating the reaction.

# 4. Experimental

# 4.1. General information

All reactions were carried out in closed glass reaction vials under an atmosphere of dry Ar. Reagents were used as obtained from commercial suppliers without further purification. Complex I was synthetized according to the reported procedure [17]. Compounds 1a, 2a, 2i, 3f, 4a-e were obtained from a commercial suppliers and used or analyzed as received. Compounds 2i [19], 3a**b** [9], **3e** [9], **4f** [9], **5a**–**j** [10], **6a**–**j** [10] were synthetized according to the reported procedures and the spectroscopic data agree with the published ones. Dry DMF was used as obtained from a commercial supplier (puriss p. a.). Flash chromatography was carried out on 60 Å (35–70 µm) silica gel (Acros Kieselgel 60) using pentane or pentane/EtOAc. pentane/Et<sub>2</sub>O or pentane/acetone mixtures as eluent. Analytical TLC was carried out on aluminum-backed plates  $(1.5 \text{ Å}, \sim 5 \text{ cm})$  pre-coated (0.25 mm) with silica gel (Merck, Silica Gel 60 F254). Compounds were visualized by exposure to UV light or by dipping the plates in a solution of 0.75%  $KMnO_4(w/v)$  in a aqueous solution of  $K_2CO_3 0.36$  M. Melting points were recorded in a metal block and are uncorrected. <sup>1</sup>H NMR spectra were recorded at 400 MHz; <sup>13</sup>C NMR spectra were recorded



Scheme 2. Substrate scope of trifluoroacetamides.<sup>a.</sup>

<sup>*a*</sup> Reaction conditions (unless otherwise noted): **5a-j** (0.1 mmol), DMF (0.3 mL), heated at the 100 °C under an argon atmosphere for 2.5 h. Yield determined by <sup>19</sup>F NMR spectroscopy using 2,2,2-trifluorotoluene as internal standard. <sup>*b*</sup> Yield without DBU as additive.

at 100 MHz, <sup>19</sup>F NMR spectra were recorded at 377 MHz with a Bruker Advance spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR chemical shifts ( $\delta$ ) are reported in ppm from tetramethylsilane, using the residual solvent resonance (CHCl<sub>3</sub>:  $\delta_H$  7.26 and CDCl<sub>3</sub>:  $\delta_C$  77.0) as an internal reference. Coupling constants (J) are given in Hz. High-resolution mass spectra (HRMS) were recorded with a Bruker microTOF ESI-TOF mass spectrometer. We were not able to obtain highresolution mass data for some of the substrates/products. Therefore, we provide EI mass data in the characterization. NMR yields were calculated using  $\alpha, \alpha, \alpha$ -trifluorotoluene or 2,2,2trifluoroacetophenone as internal standards.

# 4.2. General procedure A for the synthesis of bromodifluoroacetates **1b-f**, **1h**

In a 20 mL glass vial the corresponding alcohol (3.08 mmol, 1 equiv.) was dissolved in hexane (5 mL) under an atmosphere of air. Ethyl 2-bromo-2,2-difluoroacetate (12.3 mmol, 4 equiv., 2.5 g) was added followed by 2 drops of concentrated  $H_2SO_4$  and the reaction was stirred at room temperature for 16 h. The reaction was quenched with Na<sub>2</sub>CO<sub>3</sub> (satd. aq, 10 mL), extracted with EtOAc (3 × 10 mL) and washed with Na<sub>2</sub>CO<sub>3</sub> (satd. aq). The combined organic phases were dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. Purification by column chromatography afforded the desired esters.

# 4.2.1. Dodecyl 2-bromo-2,2-difluoroacetate (1b)

Following the general procedure A from dodecanol (573 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/Pentane 1:10) afforded the title compound as a colorless oil (801 mg, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 4.35 (t, *J*(H,H) = 6.7 Hz, 2H), 1.78–1.71 (m, 2H), 1.43–1.26 (m, 18H), 0.90–0.86 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 159.8 (t, *J*(C,F) = 31.1 Hz), 108.9 (t, *J*(C,F) = 314.3 Hz), 68.7, 32.1, 29.8, 29.7, 29.6, 29.5, 29.2, 28.3, 25.7, 22.8, 14.3. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = –60.66.

HRMS (ESI): m/z calcd for  $C_{14}H_{24}O_2^{79}BrF_2 + Na^+$ : 364.0820 [M +Na]<sup>+</sup>; found: 364.0821.

#### 4.2.2. 5-Phenylpentyl 2-bromo-2,2-difluoroacetate (1c)

Following the general procedure A from 5-phenylpentan-1-ol (505 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/ Pentane 1:10) afforded the title compound as a colorless oil (744 mg, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.30–7.26 (m, 2H), 7.20–7.16 (m, 3H), 4.35 (t, *J*(H,H) = 6.6 Hz, 2H),), 2.66–2.62 (m, 2H), 1.82–1.75 (m, 2H), 1.72–1.64 (m, 2H), 1.48–1.41 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 159.8 (t, *J*(C,F) = 31.2 Hz), 142.2, 128.5, 128.4, 125.9, 108.9 (t, *J*(C,F) = 314.3 Hz), 68.4, 35.8, 30.9, 28.1, 25.2. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = –60.72. HRMS (ESI): *m/z* calcd for C<sub>13</sub>H<sub>15</sub>O<sub>2</sub><sup>79</sup>BrF<sub>2</sub> + Na<sup>+</sup>: 343.0116 [M+Na]<sup>+</sup>; found: 343.0113.

#### 4.2.3. 1-Adamantaneethyl 2-bromo-2,2-difluoroacetate (1d)

Following the general procedure A from 1-adamantaneethanol (554 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/Pentane 1:10) afforded the title compound as a colorless oil (732 mg, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 4.41 (t, *J*(H, H) = 7.3 Hz, 2H), 2.00–1.95 (m, 3H), 1.75–1.69 (m, 3H), 1.66–1.61 (m, 3H), 1.56–1.52 (m, 8H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 159.8 (t, *J*(C,F) = 31.1 Hz), 109.0 (t, *J*(C,F) = 314.4 Hz), 65.3, 42.5, 41.9, 37.0, 31.9, 28.6. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = -60.66. HRMS (ESI): *m/z* calcd for C<sub>14</sub>H<sub>19</sub>O<sub>2</sub><sup>79</sup>BrF<sub>2</sub> + Na<sup>+</sup>: 359.0429 [M+Na]<sup>+</sup>; found: 359.0433.

# 4.2.4. (–)-Menthyl 2-bromo-2,2-difluoroacetate (1e)

Following the general procedure A from (–)-menthol (554 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/Pentane 1:10) afforded the title compound as a light yellow oil (186 mg, 19%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 4.84 (td, *J*(H,H) = 11.0, 4.5 Hz, 1H), 2.09–2.04 (m, 1H), 1.97–1.87 (m, 1H), 1.77–1.69 (m, 2H), 1.58–1.47 (m, 2H), 1.18–1.07 (m, 2H), 0.97–0.85 (m, 1H), 0.95 (d, *J*(H, H) = 6.6 Hz, 3H), 0.92 (d, *J*(H,H) = 7.0 Hz, 3H), 0.79 (d, *J*(H,H) = 7.0 Hz, 3H), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 159.4 (t, *J*(C,F) = 30.8 Hz), 109.1 (t, *J*(C,F) = 314.8 Hz), 79.7, 46.9, 40.0, 34.1, 31.6, 26.3, 23.5, 22.0, 20.7, 16.3. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = -60.63 (d, *J*(F, F) = 162.7 Hz, 1F), -61.04 (d, *J*(F,F) = 162.8 Hz, 1F). HRMS (ESI): *m*/*z* calcd for C<sub>12</sub>H<sub>19</sub>O<sub>2</sub><sup>79</sup>BrF<sub>2</sub> + Na<sup>+</sup>: 335.0429 [M+Na]<sup>+</sup>; found: 335.0429.

# 4.2.5. 2-Phenoxyethyl 2-bromo-2,2-difluoroacetate (1f)

Following the general procedure A from 2-phenoxyethanol (425 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/ Pentane 1:20) afforded the title compound as a colorless oil (405 mg, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.33–7.28 (m, 2H), 7.02–6.98 (m, 1H), 6.94–6.90 (m, 2H), 4.71–4.69 (m, 2H), 4.29–4.26 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 159.7 (t, *J*(C, F) = 31.7 Hz), 158.2, 129.7, 121.7, 114.9, 108.6 (t, *J*(C,F) = 314.1 Hz), 66.3, 65.2. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = –60.84. HRMS (ESI): *m/z* calcd for C<sub>10</sub>H<sub>9</sub>O<sub>3</sub><sup>79</sup>BrF<sub>2</sub> + Na<sup>+</sup>: 316.9595 [M+Na]<sup>+</sup>; found: 316.9599.

### 4.2.6. Benzyl 2-bromo-2,2-difluoroacetate (1h)

Following the general procedure A from benzyl alcohol (333 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/ Pentane 1:40) afforded the title compound as a colorless oil (367 mg, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.42–7.38 (m, 5H), 5.36 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 159.6 (t, *J*(C, F) = 31.5 Hz), 133.6, 129.3, 129.0, 128.7, 108.9 (t, *J*(C,F) = 314.4 Hz), 69.9. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = -60.70.

# 4.3. 6-(1,3-Dioxoisoindolin-2-yl)hexyl 2-bromo-2,2-difluoroacetate (1g)

In a 50 mL bottom flask 2-(6-hydroxyhexyl)isoindoline-1,3dione (2.0 mmol, 1 equiv., 495 mg) and Et<sub>3</sub>N (4.0 mmol, 2 equiv., 405 mg) were dissolved in dichloromethane (20 mL) under an atmosphere of argon. 2-Bromo-2,2-difluoroacetyl chloride (2.8 mmol, 1.4 equiv., 541 mg) was added dropwise and the reaction was stirred at 0 °C for 2h. The reaction was quenched with NH<sub>4</sub>Cl (satd. aq, 10 mL) and extracted with dichloromethane  $(3 \times 10 \text{ mL})$ . The combined organic phases were dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. Purification by column chromatography (SiO<sub>2</sub>; EtOAc/Pentane 1:10) afforded the title compound as a colorless oil (492 mg, 61%). <sup>1</sup>H NMR  $(400 \text{ MHz}, \text{ CDCl}_3, \text{ TMS})$ :  $\delta = 7.87 - 7.82 \text{ (m, 2H)}, 7.74 - 7.69 \text{ (m, 2H)},$ 4.34 (t, J(H,H)=6.6 Hz, 2H), 3.71-3.67 (m, 2H), 1.79-1.67 (m, 4H), 1.50-1.36 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 168.6, 159.7 (t, J(C,F)=31.2 Hz), 134.0, 132.2, 123.3, 108.9 (t, J(C,F)=314.3 Hz), 68.4, 37.9, 28.5, 28.1, 26.4, 25.3. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta = -60.71$ . HRMS (ESI): m/z calcd for  $C_{16}H_{16}O_4N^{79}BrF_2 + Na^+$ : 426.0123 [M+Na]<sup>+</sup>; found: 426.0133.

# 4.4. 2-Bromo-2,2-difluoro-1-phenylethan-1-one (1i)

Following the reported procedure with slight modifications [20]: a solution of bromobenzene (15.0 mmol, 1.1 equiv., 2.36 g) in dry Et<sub>2</sub>O (3 mL) was added dropwise to a suspension of Mg (18.0 mmol, 1.32 equiv., 437 mg) in dry Et<sub>2</sub>O (20 mL) in a sealed MW vial. The reaction was heated at 50 °C after the addition of 1.5 mL of the solution and then it was stirred at room temperature (the reaction is refluxing with the slow addition of the solution of 2-bromoethylbenzene). After the reflux is stopped, the reaction mixture was heated at 50 °C for 2 h. To a solution of ethyl 2-bromo-2,2-difluoroacetate (13.64 mmol, 1.0 equiv., 2.77 g) in dry Et<sub>2</sub>O (14 mL) at -78 °C, the readily prepared phenethylmagnesium

bromide was added dropwise and the reaction was stirred at – 78 °C for 2.5 h following by 30 min at room temperature. The reaction was quenched with HCl 3 M (10 mL) and extracted with Et<sub>2</sub>O (3 × 10 mL). The combined organic phases were dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. Purification by column chromatography (SiO<sub>2</sub>; Pentane) afforded the title compound as a colorless oil (2.23 g, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 8.17–8.14 (m, 2H), 7.71–7.67 (m, 1H), 7.56–7.52 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 181.4 (t, *J*(C, F) = 25.8 Hz), 135.2, 130.7 (t, *J*(C,F) = 2.7 Hz), 129.1, 129.0, 113.7 (t, *J*(C, F) = 318.6 Hz). <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = -57.76. (EI) *m/z* (rel intens) 105.05 (M<sup>+</sup>-CF<sub>2</sub>Br, 64), 77.15 (100).

# 4.5. 1-Bromo-1,1-difluoro-4-phenylbutan-2-one (1j)

Following the reported procedure with slight modifications [20]: a solution of 2-bromoethylbenzene (15.0 mmol, 1.1 equiv., 2.1 mL) in dry  $Et_2O(3 mL)$  was added dropwise to a suspension of Mg (18.0 mmol, 1.32 equiv., 437 mg) in dry  $Et_2O$  (20 mL) in a sealed MW vial. The reaction was heated at 50 °C after the addition of 1.5 mL of the solution and then it was stirred at room temperature (the reaction is refluxing with the slow addition of the solution of 2-bromoethylbenzene). After the reflux is stopped, the reaction mixture was heated at 50 °C for 2 h. To a solution of ethyl 2-bromo-2,2-difluoroacetate (13.64 mmol, 1.0 equiv., 2.77 g) in dry Et<sub>2</sub>O (14 mL) at  $-78 \circ \text{C}$ , the readily prepared phenethylmagnesium bromide was added dropwise and the reaction was stirred at -78°C for 2.5 h following by 30 min at room temperature. The reaction was guenched with HCl 3 M (10 mL) and extracted with Et<sub>2</sub>O ( $3 \times 10$  mL). The combined organic phases were dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. Purification by column chromatography (SiO<sub>2</sub>; EtOAc/Pentane 1:50) afforded the title compound as a colorless oil (3.01 g, 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.33-7.29 (m, 2H), 7.25-7.20 (m, 3H), 3.14-3.09 (m, 2H), 3.04-2.99 (m, 2H). <sup>13</sup>C NMR (100 MHz,  $CDCl_3$ , TMS):  $\delta = 191.3 (t, J(C,F) = 26.5 Hz)$ , 139.5, 128.8, 128.4, 126.8, 114.1 (t, J(C,F) = 319.9 Hz), 36.5, 29.1. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta = -64.90$ . HRMS (ESI): m/z calcd for  $C_{10}H_9O^{79}BrF_2 + Na^+$ : 284.9697 [M+Na]<sup>+</sup>; found: 284.9710.

4.6. General procedure *B* for the synthesis of bromo(difluoromethyl) arenes **3a-f**. Following the reported procedure with slight modifications:



To a dry flask containing a solution of aryl aldehyde (1.0 equiv.) in dry  $CH_2Cl_2$  (1.0 M) at 0 °C was added DAST (1.7 equiv.) and catalytic amounts of EtOH (50–100 µL). The reaction mixture was warmed to room temperature and stirred for 2–3 days before it was quenched at 0 °C with NaHCO<sub>3</sub> (sat. aq.) and extracted with  $CH_2Cl_2$  (3 × 30 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. Purification by column chromatography afforded the desired difluoromethyl arenes.

Under an argon atmosphere, degassed CCl<sub>4</sub> (0.35 M) was added to a round bottom flask containing the corresponding difluoromethyl arene (1.0 equiv.) and *N*-Bromosuccinimide (1.7 equiv.). The reaction mixture was irradiated by the light of a 120 W sun lamp (approx. 12 cm distance between lamp and reaction flask) for 1–30 days before being quenched with Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (sat. aq.) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. Purification by column chromatography afforded the desired bromodifluoromethyl arenes.

# 4.6.1. 1-Bromo-4-(bromodifluoromethyl)benzene (3c)

Following the general procedure B from 4-bromobenzaldehyde with a reaction time of 2 days. Purification by column chromatography (SiO<sub>2</sub>; pentane/Et<sub>2</sub>O 100:1) afforded 1-Bromo-4-(difluoromethyl)benzene as a colorless oil (1.05 g, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.62–7.58 (m, 2H), 7.41–7.36 (m, 2H), 6.61 (t, *I*(H, F) = 56.3 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 133.4 (t, J(C, F) = 22.8 Hz), 132.1, 127.4 (t, J(C,F) = 6.0 Hz), 125.3 (t, J(C,F) = 2.5 Hz), 114.3 (t, I(C,F) = 239.2 Hz). <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta = -111.10$ (d, J(F,H) = 56.3 Hz). (EI) m/z (rel intens) 207.89 (M+, <sup>81</sup>Br, 100). 205.98 (M<sup>+</sup>, <sup>79</sup>Br, 93), 127.23 (M<sup>+</sup>-Br, 49). From 1-Bromo-4-(difluoromethyl)benzene with a reaction time of 9 days. Purification by column chromatography ( $SiO_2$ ; pentane) afforded the title compound as a colorless oil (745 mg, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.62–7.58 (m, 2H), 7.50–7.46 (m, 2H). <sup>13</sup>C NMR  $(100 \text{ MHz}, \text{CDCl}_3, \text{TMS}): \delta = 137.3 (t, J(C,F) = 24.2 \text{ Hz}), 132.1, 126.1 (t, J)$ (C,F) = 5.1 Hz, 126.0 (t, J(C,F) = 1.7 Hz), 117.8 (t, J(C,F) = 303.7 Hz). <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta = -44.05$  (s). (EI) m/z (rel intens) 207.19 (M<sup>+79</sup>Br-Br, 96), 205.17 (M<sup>+81</sup>Br-Br, 100), 126.23 (M<sup>+</sup>-Br<sub>2</sub>, 47).

# 4.6.2. 1-(Bromodifluoromethyl)-4-(trifluoromethoxy)benzene (**3d**)

Following the general procedure B from 4-(trifluoromethoxy) benzaldehyde with a reaction time of 3 days. Purification by column chromatography (SiO<sub>2</sub>; pentane/Et<sub>2</sub>O 100:1) afforded 1-(difluoromethyl)-4-(trifluoromethoxy)benzene as a colorless volatile liquid (494 mg, 34%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.58–7.54 (m, 2H), 7.33–7.28 (m, 2H), 6.66 (t, *I*(H,F) = 56.3 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 151.0 (q, *I*(C,F) = 1.9 Hz), 133.1 (t, J(C,F) = 22.9 Hz), 127.5 (t, J(C,F) = 6.0 Hz), 121.2, 120.5 (q, J(C,F) = 6.0 Hz), 121.2, 1 F) = 258.1 Hz), 114.0 (t, J(C,F) = 239.3 Hz). <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta = -57.84$  (s, 3F), -110.79 (d, I(F,H) = 56.2 Hz, 2F). (EI) m/z (rel intens) 211.99 (M<sup>+</sup>, 84), 193.19 (M<sup>+</sup>-F, 22), 162.19 (20), 145.19 (33), 127.23 (M<sup>+</sup>-OCF<sub>3</sub>, 100). From 1-(difluoromethyl)-4-(trifluoromethoxy)benzene with a reaction time of 14 days. Purification by column chromatography (SiO<sub>2</sub>; pentane) afforded the title compound as a colorless oil (237 mg, 47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.69–7.64 (m, 2H), 7.33–7.28 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 151.2 (p, J(C,F) = 2.1 Hz), 136.7 (t, J(C, F) = 24.4 Hz), 126.5 (t, J(C,F) = 5.1 Hz), 121.0, 120.4 (q, J(C,F)F) = 258.7 Hz), 117.0 (t, J(C,F) = 303.7 Hz). <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta = -43.70$  (s, 2F), -57.80 (s, 3F). (EI) m/z (rel intens) 211.04 (M<sup>+</sup>-Br, 100), 145.21 (25).

# 4.7. General procedure C for the halogen exchange reaction using $(PPh_3)_3CuF$

A reaction vial was charged with the corresponding bromodifluoderivative **1a-i**, **5h-***j* (0.1 mmol, 1 equiv.), (PPh<sub>3</sub>)<sub>3</sub>CuF (0.14 mmol, 1.4 equiv., 122 mg) and dry DMF (0.3 mL) under an atmosphere of argon. The reaction was stirred at 100 °C for 2.5 h. The reaction was cooled down and  $\alpha,\alpha,\alpha$ -trifluorotoluene (3 equiv., 37 µL) was added as internal standard and the yield was calculated by <sup>19</sup>F NMR spectroscopy.

## 4.8. General procedure D for the synthesis of trifluoroacetates 2b-h

In a 20 mL glass vial the corresponding alcohol (3.0 mmol, 1 equiv.) was dissolved in hexane (5 mL) under an atmosphere of air. Ethyl 2,2,2-trifluoroacetate (12.0 mmol, 4 equiv., 1.7 g) was added followed by 2 drops of concentrated  $H_2SO_4$  and the reaction was stirred at room temperature for 16 h. The reaction was quenched with Na<sub>2</sub>CO<sub>3</sub> (satd. aq, 10 mL), extracted with EtOAc (3 × 10 mL) and washed with Na<sub>2</sub>CO<sub>3</sub> (satd. aq. 20 mL). The combined organic

phases were dried over MgSO<sub>4</sub> and the solvent was removed under reduced pressure. Purification by column chromatography afforded the desired esters.

# 4.8.1. Dodecyl 2,2,2-trifluoroacetate (**2b**)

Following the general procedure D from dodecanol (559 mg). Purification by column chromatography (SiO2; Pentane) afforded the title compound as a colorless oil (700 mg, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 4.34 (t, *J*(H,H) = 6.7 Hz, 2H), 1.77–1.70 (m, 2H), 1.42–1.23 (m, 18H), 0.90–0.86 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 157.7 (q, *J*(C,F) = 42.0 Hz), 114.8 (q, *J*(C,F) = 285.5 Hz), 68.4, 32.1, 29.8, 29.7, 29.6, 29.5, 29.2, 28.3, 25.7, 22.9, 14.2. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = –75.37. (EI) *m/z* (rel intens) 213.14 (M<sup>+</sup>-CF<sub>3</sub>, 6), 97.23 (26), 83.33 (47), 69.34 (88), 67.52 (100).

### 4.8.2. 5-Phenylpentyl 2,2,2-trifluoroacetate (2c)

Following the general procedure D from 5-phenylpentan-1-ol (493 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/ Pentane 1:10) afforded the title compound as a colorless oil (520 mg, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.30–7.26 (m, 2H), 7.21–7.16 (m, 3H), 4.34 (t, *J*(H,H) = 6.7 Hz, 2H),), 2.65–2.61 (m, 2H), 1.81–1.74 (m, 2H), 1.71–1.64 (m, 2H), 1.47–1.39 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 157.7 (q, *J*(C,F) = 42.0 Hz), 142.2, 128.5, 128.4, 125.9, 114.7 (q, *J*(C,F) = 285.6 Hz), 68.3, 35.8, 31.0, 28.1, 25.2. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = –75.12. (EI) *m/z* (rel intens) 259.86 (M<sup>+</sup>, 20), 146.17 (100), 117.29 (50), 104.56 (75), 91.42 (95).

#### 4.8.3. 1-Adamantaneethyl 2,2,2-trifluoroacetate (2d)

Following the general procedure D from 1-adamantaneethanol (541 mg). Purification by column chromatography (SiO<sub>2</sub>; Pentane) afforded the title compound as a colorless oil (629 mg, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 4.39 (t, *J*(H,H) = 7.4 Hz, 2H), 1.99–1.93 (m, 3H), 1.75-1.69 (m, 3H), 1.67–1.60 (m, 3H), 1.57–1.50 (m, 8H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 157.6 (q, *J*(C,F) = 42.0 Hz), 114.7 (q, *J*(C,F) = 285.7 Hz), 64.9, 42.5, 41.9, 37.0, 31.9, 28.7. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = -75.56. (EI) *m/z* (rel intens) 207.12 (M<sup>+</sup>-CF3, 1), 163.13 (4), 132.12 (100), 93.43 (29), 79.47 (32).

# 4.8.4. (-)-Menthyl 2,2,2-trifluoroacetate (2e)

Following the general procedure D from (–)-menthol (444 mg). Purification by column chromatography (SiO<sub>2</sub>; Et<sub>2</sub>O/Pentane 1:20) afforded the title compound as a colorless oil (249 mg, 35%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 4.87 (td, *J*(H,H) = 11.0, 4.5 Hz, 1H), 2.09–2.01 (m, 1H), 1.91–1.78 (m, 1H), 1.77–1.67 (m, 2H), 1.59–1.45 (m, 2H), 1.19–1.03 (m, 2H), 0.97–0.88 (m, 1H), 0.94 (d, *J*(H, H) = 6.6 Hz, 3H), 0.91 (d, *J*(H,H) = 7.0 Hz, 3H), 0.78 (d, *J*(H,H) = 7.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 157.3 (q, *J*(C,F) = 41.6 Hz), 114.8 (q, *J*(C,F) = 285.7 Hz), 79.5, 46.9, 40.2, 34.1, 31.6, 26.4, 23.6, 21.9, 20.6, 16.3. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = -75.30. (EI) *m/z* (rel intens) 139.02 (M<sup>+</sup>-CO<sub>2</sub>CF<sub>3</sub>, 17), 123.11 (9), 95.13 (44), 81.24 (100), 79.36 (52), 67.41 (54).

# 4.8.5. 2-Phenoxyethyl 2,2,2-trifluoroacetate (2f)

Following the general procedure D from 2-phenoxyethanol (409 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/Pentane 1:9) afforded the title compound as a colorless oil (184 mg, 27%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.34–7.28 (m, 2H), 7.03–6.98 (m, 1H), 6.93–6.89 (m, 2H), 4.72–4.68 (m, 2H), 4.29–4.25 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 158.2, 157.6 (q, *J*(C, F)=42.8 Hz), 129.7, 121.7, 114.8, 114.6 (q, *J*(C,F)=285.4 Hz), 66.2, 65.0. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = –74.88. (EI) *m/z* (rel intens) 234.03 (M<sup>+</sup>, 29), 141.12 (100).

# 4.8.6. 6-(1,3-Dioxoisoindolin-2-yl)hexyl 2,2,2-trifluoroacetate (2g)

Following the general procedure D from 2-(6-hydroxyhexyl) isoindoline-1,3-dione (432 mg). Purification by column chromatography (SiO<sub>2</sub>; EtOAc/Pentane 1:4) afforded the title compound as a white solid (243 mg, 41%). M.p. = 57–60 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.86–7.82 (m, 2H), 7.73–7.69 (m, 2H), 4.35–4.31 (m, 2H), 3.71–3.67 (m, 2H), 1.78–1.66 (m, 4H), 1.48–1.35 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 168.3, 157.4 (q, *J*(C,F) = 42.1 Hz), 133.9, 132.1, 123.1, 114.5 (q, *J*(C,F) = 285.7 Hz), 68.1, 37.7, 28.3, 28.0, 26.3, 25.1. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = –75.13. (EI) *m/z* (rel intens) 234.99 (M<sup>+</sup>, 46), 274.16 (1), 230.10 (7), 160.22 (100), 77.48 (18).

# 4.8.7. Benzyl 2,2,2-trifluoroacetate (2h)

Following the general procedure D from benzyl alcohol (324 mg). Purification by column chromatography (SiO<sub>2</sub>; Pentane) afforded the title compound as a colorless oil (310 mg, 51%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.43–-7.36 (m, 5H), 5.36 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 157.5 (q, *J*(C,F) = 42.5 Hz), 133.4, 129.4, 129.0, 128.8, 114.7 (q, *J*(C,F) = 285.7 Hz), 69.7. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>):  $\delta$  = -74.96. (EI) *m/z* (rel intens) 203.93 (M<sup>+</sup>, 45), 135.18 (12), 107.23 (30), 91.41 (100).

# Acknowledgments

Support from the Swedish Research Council, the Knut and Alice Wallenbergs Foundation, AstraZeneca and Stockholm Brain Institutet is gratefully acknowledged. A. B. G. thanks the AstraZeneca Postdoctoral Programme for funding a postdoctoral contract.

#### References

- H.-J. Böhm, D. Banner, S. Bendels, M. Kansy, B. Kuhn, K. Müller, U. Obst-Sander, M. Stahl, Fluorine in medicinal chemistry, ChemBioChem 5 (2004) 637–643.
- [2] C.N. Neumann, T. Ritter, Late-stage fluorination: fancy novelty or useful tool? Angew. Chem. Int. Ed. 54 (2015) 3216–3221.
- [3] K. Chansaenpak, B. Vabre, F.P. Gabbai, [<sup>18</sup>F]-group 13 fluoride derivatives as radiotracers for positron emission tomography, Chem. Soc. Rev. 45 (2016) 954– 971.
- [4] S. Preshlock, M. Tredwell, V. Gouverneur, <sup>18</sup>F-labeling of arenes and heteroarenes for applications in positron emission tomography, Chem. Rev. 116 (2016) 719–766.
- [5] C. Hollingworth, V. Gouverneur, Transition metal catalysis and nucleophilic fluorination, Chem. Commun. 48 (2012) 2929–2942.
- [6] C.-G. Zhan, D.A. Dixon, Hydration of the fluoride anion: structures and absolute hydration free energy from first-principles electronic structure calculations, J. Phys. Chem. A 108 (2004) 2020–2029.
- [7] T.M. Sokolenko, K.I. Petko, L.M. Yagupolskii, N-trifluoromethylazoles, Chem. Heterocycl. Compd. 45 (2009) 430–435.
- [8] S. Verhoog, L. Pfeifer, T. Khotavivattana, S. Calderwood, T.L. Collier, K. Wheelhouse, M. Tredwell, V. Gouverneur, Silver-mediated 18F-labeling of Aryl-CF<sub>3</sub> and Aryl-CHF<sub>2</sub> with <sup>18</sup>F-fluoride, Synlett 27 (2016) 58.
   [9] T. Khotavivattana, S. Verhoog, M. Tredwell, L. Pfeifer, S. Calderwood, K.
- [9] T. Khotavivattana, S. Verhoog, M. Tredwell, L. Pfeifer, S. Calderwood, K. Wheelhouse, T. LeeCollier, V. Gouverneur, 18F-labeling of Aryl-SCF<sub>3</sub>, -OCF<sub>3</sub> and -OCHF<sub>2</sub> with [<sup>18</sup>F]fluoride, Angew. Chem. Int. Ed. 54 (2015) 9991–9995.
- [10] A. Bermejo Gomez, M. Cortes, M. Luebcke, M. Johansson, C. Halldin, K.J. Szabo, M. Schou, Efficient DBU accelerated synthesis of <sup>18</sup>F-labelled trifluoroacetamides, Chem. Commun. 52 (2016) 13963–13966.
- [11] H. Shi, A. Braun, L. Wang, S.H. Liang, N. Vasdev, T. Ritter, Synthesis of <sup>18</sup>Fdifluoromethylarenes from aryl (pseudo) halides, Angew. Chem. Int. Ed. 55 (2016) 10786–10790.
- [12] F.H. Jardine, L. Rule, A.G. Vohra, The chemistry of copper(I) complexes. Part I. Halogeno-complexes, J. Chem. Soc. A (1970) 238–240.
- [13] D.J. Culliver, W. Levason, M. Webster, Coordination stabilised copper(I) flouride. Crystal and molecular structure of fluorotris(triphenylphosphine) copper(I)-ethanol (1/2), Cu(PPh<sub>3</sub>)<sub>3</sub> P-2EtOH, Inorg. Chim. Acta 52 (1981) 153– 159.
- [14] M.K. Chaudhuri, S.S. Dhar, N. Vijayashree, Molecular complexes of copper(I): easy access to CuF(PPh<sub>3</sub>)<sub>3</sub>·2ROH (R = Me or Et), Transit. Metal Chem. 25 (2000) 559–561.
- [15] O.A. Tomashenko, E.C. Escudero-Adán, M. MartínezBelmonte, V.V. Grushin, Simple stable, and easily accessible well-defined CuCF<sub>3</sub> aromatic trifluoromethylating agents, Angew. Chem. Int. Ed. 50 (2011) 7655–7659.

- [16] I.S. Atipin, A.I. Vigalok, A.I. Konovalov, Copper fluoride phosphine complex [Cu (PPh<sub>3</sub>)F] – a new reagent for synthesis of aromatic fluorides, Zh. Org. Khim. 27 (1991) 1577.
- [17] J.M. Larsson, S.R. Pathipati, K.J. Szabó, Regio- and stereoselective allylic trifluoromethylation and fluorination using CuCF<sub>3</sub> and CuF reagents, J. Fluorine Chem. 78 (2013) 7330–7336.
- [18] H. Martinez, A. Rebeyrol, T.B. Nelms, W.R. Dolbier Jr., Impact of fluorine substituents on the rates of nucleophilic aliphatic substitution and β-elimination, J. Fluorine. Chem. 135 (2012) 167–175.
- [19] K. Fuchibe, H. Jyono, M. Fujiwara, T. Kudo, M. Yokota, J. Ichikawa, Domino Friedel–Crafts-type cyclizations of difluoroalkenes promoted by the α-cationstabilizing effect of fluorine: an efficient method for synthesizing angular PAHs, Chem. Eur. J. 17 (2011) 12175–12185.
- [20] T. Nihei, N. Iwai, T. Matsuda, T. Kitazume, Stereocontrolled synthesis of  $\beta$ -difluoromethylated materials, J. Org. Chem. 70 (2005) 5912–5915.